StockNews.AI
XBIO
StockNews.AI
153 days

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

1. Encouraging preclinical data supports DNase technology for tough cancers. 2. XBIO advances towards IND and first-in-human studies for pancreatic carcinoma.

Earnings
+3.32%Current Return
VS
+0.57%S&P 500
$3.4603/19 08:14 AM EDTEvent Start
$3.57503/20 02:44 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical data can enhance investor confidence, similar to past successful biotech trials that led to price surges.

How important is it?

Preclinical data and clinical trial progress can significantly influence investor sentiment and potential future partnerships.

Why Long Term?

The successful development timeline towards human studies is likely to yield long-term value for XBIO.

Related Companies

VRTXAMGNKITE
Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma FRAMINGHAM, MA / ACCESS Newswire / March 19, 2025 / Xenetic Biosciences, Inc.  (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2024. Recent Highlights Extended its collaborations with the University of Virginia and Scripps Research through 2025; Entered into a Clinical Trial Services Agreement with PeriNess Ltd.

Related News